Clinical Trials Browser

OTHER × Pancreatic Cancer Resectable × nimotuzumab × Clear all

NCT06722911 2024-12-09

Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer

Phase 2 Recruiting

Gastrointestinal

Pancreatic Cancer Resectable